Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene, Strand Team on HPV Test

NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into a memorandum of understanding with Strand Life Sciences, under which Strand will license and validate Trovagene's human papillomavirus urine test and high-risk HPV DNA assay.

Bangalore, India-based Strand will have rights to offer the test in India and countries in the South Asian Association for Regional Cooperation for clinical diagnostic and carrier screening applications. Strand intends to perform analytical and clinical validation studies on the assay technology in its target markets, with an initial study of the diagnostic accuracy using urine as a specimen in various stages of disease progression.

Strand also intends to validate the clinical utility of HPV DNA testing as a risk indicator and pathological cause of oral cancer in buccal swabs, biopsies, and saliva/sputum specimens.

Further terms of the agreement were not disclosed.

"The potential to use urine, an easily obtained and stable testing sample, for high-risk HPV carrier screening across medically underserved areas is very promising," Vijay Chandru, chairman and CEO of Strand, said in a statement.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.